Q3
Valeant’s tough year gets worse with Q3 loss of $1.22 billion
November 9, 2016Research and Development Q3, Valeant, loss
It’s easy to say that Valeant hasn’t had a great year so far. Unfortunately for those concerned, the outlook for …
Lundbeck sales slide as generic competition bites
November 6, 2014Sales and Marketing Ebixa, Lundbeck, Q3, Xenazine, generic, onfi, sabril
Lundbeck’s sales fell dramatically in the third quarter of 2014 as it struggles with expiring patents, although several of its …
AbbVie financials beat expectations
October 31, 2014Sales and Marketing AbbVie, Abbott, Creon, Humira, Iopinavir/ritonavir, Kaletra, Q3, Synthroid, levothyroxine, pancrelipase
AbbVie has announced higher-than-expected financial results for the third quarter of 2014, although it continues to rely heavily on blockbuster …
Merck revenue falls
October 28, 2014Manufacturing and Production, Sales and Marketing Frazier, Merck, Q3, Victrelis, hep C, sovaldi
Merck has posted a set of disappointing financials for the latest quarter as it cuts cost across its business to …
Celgene expands immunotherapy pipeline with Sutro
October 27, 2014Research and Development, Sales and Marketing Celgene, PD-1 and PD-L1, Q3, oncology, sutro
Celgene has extended its collaboration with Sutro Biopharma and added a buyout option for the firm as the two companies …
Lacklustre sales hit Lilly again
October 24, 2014Sales and Marketing Q3, cymbalta, humilin, lilly, sales, zyprexa
Lilly is enduring one of the bleakest financial years in its history as patent expiries continue to take chunks out …
GSK mulls $27 billion ViiV sell-off
October 23, 2014Medical Communications, Sales and Marketing AIDS, Advair, GSK, HIV, Pfizer, Q3, Shionogi, Tivicay, ViiV
After a difficult few years and another poor quarter, GlaxoSmithKline has announced that it is looking to float its fast-growing …
New cancer drugs escalate Roche earnings
October 16, 2014Research and Development, Sales and Marketing Cancer, Herceptin (trastuzumab), Kadcyla, Perjeta, Q3, Roche, ado-trastuzumab emtansine, pertuzumab
Roche’s sales saw solid growth in the first nine months of the year, increased by the firm’s new cancer medicines. …
More changes at the top as AstraZeneca profits slip
November 1, 2013Sales and Marketing AstraZeneca, Crestor, Q3, profits
AstraZeneca’s third quarter revenues and profits fell below analysts’ expectations yesterday, but mitigated the news with the appointment of a …
Cancer drugs lift Pfizer in third quarter
October 30, 2013Sales and Marketing Lipitor, Lyrica, Pfizer, Q3, Xalkori
Pfizer saw a drop in revenue for the third quarter but the future looks bright as new products begin to …
Strong sales for Biogen Idec’s MS drug
October 29, 2013Sales and Marketing Biogen IDEC, Q3, gilenya, tecfidera
Biogen Idec’s oral multiple sclerosis (MS) drug Tecfidera lived up to its blockbuster-in-waiting billing with third quarter sales that exceeded …
Corruption probe hits GSK
October 24, 2013Sales and Marketing China, GSK, Q3, corruption
The fallout from corruption investigations in China has hit GlaxoSmithKline, which announced third quarter sales in the country were down …
Novartis sees profit slip
October 23, 2013Sales and Marketing Afinitor, Diovan, Novartis, Q3, gilenya
Novartis saw generic competition erode profit in the third quarter of the year, although sales across the group actually rose …
Johnson & Johnson posts strong Q3 results
October 16, 2013Sales and Marketing J&J, JJ, Q3, Velcade, results
Johnson & Johnson has posted a strong set of financials for the third quarter as new products from its pharma …
Pfizer stumbles in third quarter
November 2, 2012Research and Development, Sales and Marketing Ian Read, Lipitor, Pfizer, Prevnar, Q3
Pfizer has experienced a worse than expected third quarter, due to disappointing sales of paediatric vaccine Prevnar and a surprise …
Latest content
